Dynorphin A(1-13) analgesia in opioid-treated patients with chronic pain. A controlled pilot study

Clinical Drug Investigation

Volumn 17, Issue 1, 1999, Pages 33-42

  Portenoy, Russell K ^a   Caraceni, Augusto ^a   Cherny, Nathan I ^a   Goldblum, Ronald ^b   Ingham, Jane ^a   Inturrisi, Charles E ^c   Johnson, Jian H ^b   Lapin, Jeanne ^a   Tiseo, Paul J ^a   Kreek, Mary Jeanne ^d  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b Neurobiological Technologies Inc   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; DYNORPHIN[1-13]; HYDROMORPHONE; MORPHINE; OPIATE;

ADULT; ANALGESIA; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUSHING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOOD; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; STATISTICAL ANALYSIS; SWEATING; VERTIGO; XEROSTOMIA;

EID: 0032959282     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199917010-00004     Document Type: Article

References (32)

1. Smith AP, Lee NM. Pharmacology of dynorphin. Ann Rev Pharmacol Toxicol 1988; 28: 123-40
2. 1-13 administration causes elevation of serum levels of prolactin in human subjects. In: Harris LS, editor. Problems of drug dependence 1993. Proceedings of the 55th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series. Supt. of Docs., US Govt. Printing Office, Washington DC, NIH publication No. 94-3749, Vol 141. 1994: 108
3. Goldstein A, Tachibana S, Lowney LI, et al. Dynorphin (1-13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci USA 1979; 76: 6666-70
4. Huidobro-Toro JP, Yoshimura K, Lee NM, et al. Dynorphin interaction at the κ-opiate site. Eur J Pharmacol 1981; 72: 265-6
5. Garzo J, Sanchez-Blazquez P, Gerhart J, et al. Dynorphin 1-13: interaction with other opiate ligand bindings in vitro. Brain Res 1984; 302: 392-6
6. James IF, Goldstein A. Site-directed alkylation of multiple opioid receptors. Mol Pharmacol 1984; 25: 337-42
7. Nakazawa T, Ikeda M, Kaneko T, et al. Analgesic effects of dynorphin - A and morphine in mice. Peptides 1985; 6: 75-8
8. Hayes AG, Skingle M, Tyers MB. Antinociceptive profile of dynorphin in the rat. Life Sci 1983; 33 (1 Suppl.): 657-60
9. Tiseo PJ, Geller EB, Adler MW. Antinociceptive action of intracerebroventricularly administered dynorphin and other opioid peptides in the rat. J Pharmacol Exp Ther 1988; 246: 449-53
10. (1-17) J Pharmacol Exp Ther 1990; 252: 539-45
11. Friedman HJ, Jen MF, Chang JH. Dynorphin: a possible modulatory peptide on morphine or beta-endorphin analgesia in mouse. Eur J Pharmacol 1981; 69: 357-60
12. Chavkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand of the kappa-opioid receptor. Science 1982; 215: 413-5
13. Walker JM, Moises HC, Coy DH, et al. Dynorphin (1-17): lack of analgesia but evidence for non-opiate electrophysiological and motor effect. Life Sci 1982; 31: 1821-4
14. Tulunay FC, Jen MF, Chang JK, et al. Possible regulatory role of dynorphin on morphine- and beta-endorphin-induced analgesia. J Pharm Exp Ther 1981; 76: 235-9
15. Aceto MD, Dewey WL, Chang JK, et al. Dynorphin-1-13 substitutes for morphine in addicted rhesus monkeys. Eur J Pharmacol 1982; 83: 139-44
16. Hooke LP, He L, Lee NM. Dynorphin A modulates acute and chronic opioid effects. J Pharmacol Exp Ther 1995; 273: 292-7
17. 1| dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice. J Pharmacol Exp Ther 1993; 266: 121-4
18. Wen HI, Ho WK. Suppression of withdrawal symptoms by dynorphin in heroin addicts. Eur J Pharmacol 1984; 82: 183-6
19. Shen KF, Crain SM. Specific N- or C-terminus modified dynorphin and beta-endorphin peptides can selectively block excitatory opioid receptor functions in sensory neurons and unmask potent inhibitory effects of opioid agonists. Brain Res 1995; 673: 30-8
20. Herman BH, Goldstein A. Antinociception and paralysis induced by intrathecal dynorphin A. J Pharmacol Exp Ther 1985; 232: 27-32
21. Spampinato S, Gandeletti S. Characterization of dynorphin A-induced nociception at spinal level. Eur J Pharmacol 1985; 110: 21-30
22. Jhamandas K, Sutak M, Lemaire S. Comparative analgesic action of dynorphin 1-8, dynorphin 1-13, and a receptor agonist U-50,488. Can J Physiol Pharmacol 1986; 64: 263-8
23. Stevens CW, Yaksh TL. Dynorphin A and related peptides administered intrathecally in the rat: a search for putative opiate receptor activity. J Pharmocol Exp Ther 1986; 238: 833-8
24. 1| dynorphin A-(2-17) has naloxone-insensitive antinociceptive effect in the writhing assay. J Pharmacol Exp Ther 1995; 273: 802-7
25. Wen HL, Ong BH, Ho WK, et al. Treatment of pain in cancer patients with dynorphin 1-10 amide. In: Muller EE, Genazzani AR, editors. Central and peripheral endorphins: basic and clinical aspects. New York: Raven Press, 1984: 319-23
26. Wen HL, Mehal ZD, Ong BH, et al. Intrathecal administration of beta-endorphin and dynorphin-(1-13) for the treatment of intractable pain. Life Sci 1985; 37: 1213-20
27. Wen HL, Mehal ZD, Ong BH, et al. Treatment of pain in cancer patients by intrathecal administration of dynorphin. Peptides 1987; 8: 191-3
28. Muller S, Hochhaus G. Metabolism of dynorphin A (1-13) in human blood and plasma. Pharm Res 1995; 12: 1165-70
29. Goli V, Urban B, Gayam R, et al. Side effects of dynorphin in patients on long-term methadone therapy [abstract]. In: Abstracts, 7th World Congress on Pain, Seattle. IASP Publications, 1993: 310
30. Fishman B, Pasternak S, Wallenstein SL, et al. The Memorial Pain Assessment Card: a valid instrument for the assessment of cancer pain. Cancer 1987; 60: 1151-7
31. Chou JZ, Kreek MJ, Chait BT. Matrix-assisted laser desorption mass spectrometry of biostranformation products of dynorphin A in vitro. J Am Soc Mass Spectrom 1994; 5: 10-6
32. Chou JZ, Chait BT, Wang R, et al. Differential biotransformation of dynorphin A (1-17) and dynorphin A (1-13) peptides in human blood, ex vivo. Peptides 1996; 17: 983-9